Can a simple protein infusion prevent deadly Re-Bleeding in cirrhosis patients?
NCT ID NCT07395141
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding albumin to standard treatment reduces re-bleeding and death in adults with cirrhosis who have acute variceal bleeding. Sixty participants will be randomly assigned to receive either albumin for three days plus standard care, or standard care alone. The main outcomes are re-bleeding during hospitalization and at six weeks, as well as in-hospital mortality.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Albumin
What this could lead to
If it works, this could show that adding albumin to standard treatment helps prevent re-bleeding and improves survival in people with cirrhosis and acute variceal bleeding.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Albumin is generally safe, but it may not provide significant benefit over standard care alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr Sumit Rungta
Lucknow, Uttar Pradesh, 206003, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact